cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biogen Inc
59 own
50 watching
Current Price
$302.41
$6
(2.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
43,788.97M
52-Week High
52-Week High
319.74
52-Week Low
52-Week Low
188.535
Average Volume
Average Volume
1.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
26.7899
iconMarket Capitalization43,788.97M
icon52-Week High319.74
icon52-Week Low188.535
iconAverage Volume1.03M
iconDividend Yield--
iconP/E Ratio26.7899
What does the Biogen Inc do?
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Biogen Inc make?
News & Events about Biogen Inc.
Ticker Report
28days ago
Biogen Inc. (NASDAQ:BIIB Get Rating) EVP Ginger Gregory sold 2,681 shares of the firms stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $300.00, for a total transaction of $804,300.00. Following the transaction, the executive vice president ...
Zolmax
1month ago
Biogen Inc. (NASDAQ:BIIB Get Rating) Equities researchers at Jefferies Financial Group reduced their Q3 2023 earnings per share estimates for Biogen in a note issued to investors on Tuesday, April 25th. Jefferies Financial Group analyst M. Yee now anticipates that the biotechnology company will earn...
Business Wire
1month ago
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter ended March 31, 2023. The following information represents select highlights from the full UK annual report...
Fool.com Headlines
1month ago
One is slightly cheaper than the other.When you think of biotech investing, you might focus on small companies that are years away from product revenue. They may eventually offer great rewards -- but at the moment, risk is high. If you're more of a cautious investor, that may not be your thing. That...
Benzinga
1month ago
Latest Ratings for BIIB DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy View More Analyst Ratings for BIIB View the Latest Analyst Ratings read more...
Frequently Asked Questions
Frequently Asked Questions
What is Biogen Inc share price today?
plus_minus_icon
Can Indians buy Biogen Inc shares?
plus_minus_icon
How can I buy Biogen Inc shares from India?
plus_minus_icon
Can Fractional shares of Biogen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biogen Inc stocks?
plus_minus_icon
What is today’s traded volume of Biogen Inc?
plus_minus_icon
What is today’s market capitalisation of Biogen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biogen Inc?
plus_minus_icon
What percentage is Biogen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biogen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$302.41
$6
(2.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00